Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4449849
Max Phase: Preclinical
Molecular Formula: C33H36Cl3N5O4
Molecular Weight: 673.04
Molecule Type: Unknown
Associated Items:
ID: ALA4449849
Max Phase: Preclinical
Molecular Formula: C33H36Cl3N5O4
Molecular Weight: 673.04
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CNC(=O)C[C@@H](Cc1ccc(Cl)c(Cl)c1)NC(=O)CN1C(=O)[C@@H](NC(=O)C[C@@H](N)Cc2ccc(Cl)cc2)CCc2ccccc21
Standard InChI: InChI=1S/C33H36Cl3N5O4/c1-38-30(42)18-25(15-21-8-12-26(35)27(36)16-21)39-32(44)19-41-29-5-3-2-4-22(29)9-13-28(33(41)45)40-31(43)17-24(37)14-20-6-10-23(34)11-7-20/h2-8,10-12,16,24-25,28H,9,13-15,17-19,37H2,1H3,(H,38,42)(H,39,44)(H,40,43)/t24-,25+,28-/m0/s1
Standard InChI Key: SWUZVPHIPZJBBD-OARDWFSCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 673.04 | Molecular Weight (Monoisotopic): 671.1833 | AlogP: 4.23 | #Rotatable Bonds: 12 |
Polar Surface Area: 133.63 | Molecular Species: BASE | HBA: 5 | HBD: 4 |
#RO5 Violations: 1 | HBA (Lipinski): 9 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 12.38 | CX Basic pKa: 8.93 | CX LogP: 3.96 | CX LogD: 2.43 |
Aromatic Rings: 3 | Heavy Atoms: 45 | QED Weighted: 0.23 | Np Likeness Score: -0.66 |
1. Balazs AYS, Carbajo RJ, Davies NL, Dong Y, Hird AW, Johannes JW, Lamb ML, McCoull W, Raubo P, Robb GR, Packer MJ, Chiarparin E.. (2019) Free Ligand 1D NMR Conformational Signatures To Enhance Structure Based Drug Design of a Mcl-1 Inhibitor (AZD5991) and Other Synthetic Macrocycles., 62 (21): [PMID:31361481] [10.1021/acs.jmedchem.9b00716] |
2. Johannes JW, Bates S, Beigie C, Belmonte MA, Breen J, Cao S, Centrella PA, Clark MA, Cuozzo JW, Dumelin CE, Ferguson AD, Habeshian S, Hargreaves D, Joubran C, Kazmirski S, Keefe AD, Lamb ML, Lan H, Li Y, Ma H, Mlynarski S, Packer MJ, Rawlins PB, Robbins DW, Shen H, Sigel EA, Soutter HH, Su N, Troast DM, Wang H, Wickson KF, Wu C, Zhang Y, Zhao Q, Zheng X, Hird AW.. (2017) Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors., 8 (2): [PMID:28197319] [10.1021/acsmedchemlett.6b00464] |
Source(1):